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Abstract
Background and Objective Intravesical instillation of
glycosaminoglycans is a promising option for the treatment
of chronic cystitis, as it supports the regeneration of the
damaged urothelial layer. We investigated the efficacy of
short-term intravesical chondroitin sulphate treatment (six
courses of instillation) in patients with chronic radiother-
apy- or chemotherapy-associated cystitis.
Methods This prospective, observational study included
patients with chronic radiotherapy- or chemotherapy-associ-
ated cystitis, who received six once-weekly intravesical
instillations of 0.2 % chondroitin sulphate 40 mL. Every
week, patients recorded their symptoms and their benefits and
tolerance of treatment, using a self-completed questionnaire.
Results The study included 16 patients (mean age
68.5 years; 50 % male). During the study, a reduction in all
evaluated parameters was observed. After one dose of
chondroitin sulphate, symptom improvement was observed
in 38 % of patients, and after the second dose, an additional
31 % of patients showed improvement. At week 6, 80 % of
patients had either improved or were symptom free, and
significant improvements in urinary urgency (p = 0.0082),
pollakisuria (p = 0.0022), urge frequency (p = 0.0033)
and lower abdominal pain (p = 0.0449) were observed.
Haematuria, present in 9 of the 16 patients at baseline, was
completely resolved in all cases after 6 weeks. The
majority of patients (93 %) evaluated the tolerance of
chondroitin sulphate as ‘good’ or ‘very good’. No treat-
ment-related adverse events were reported.
Conclusion Intravesical administration of chondroitin
sulphate was effective for the treatment of radiotherapy- or
chemotherapy-associated cystitis. Even short-term treat-
ment appears to be effective in reducing symptoms and
improving the quality of life of patients.
Key Points
Intravesically applied chondroitin sulphate was a
safe and well-tolerated therapeutic option for the
treatment of radiotherapy- or chemotherapy-
associated cystitis.
Even brief treatment with intravesically applied
chondroitin sulphate produced rapid symptom
improvement in the majority of patients.
This benefit of glycosaminoglycan replacement
therapy positively influences the acceptance of
oncological therapies.
1 Introduction
Nonbacterial cystitis is a common adverse event of radio-
therapy and chemotherapy in patients with pelvic tumours.
In radiotherapy-associated cystitis, a differentiation is
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made between the acute and late forms of the disease.
Acute toxicity phenomena normally occur 2–3 weeks after
the start of radiation to pelvic organs. The symptoms
generally resolve spontaneously; however, they lead to a
significant decrease in the quality of life [1] and thus affect
the acceptance of oncological therapy. The late form of
radiogenic cystitis is associated with chronic changes of the
bladder wall, which start 6 months after radiotherapy.
These alterations lead to vascular and muscle changes and
increase the susceptibility to mucosal ulceration and
haemorrhage [2]. Approximately 85 % of patients with
prostate cancer receiving external radiotherapy (74 Gy)
and 24 % of patients with cervical carcinoma receiving
brachytherapy develop acute radiogenic cystitis [2, 3].
Recurrent haematuria, a severe symptom of cystitis, which
requires surgical intervention, occurs in approximately 8 %
of patients 3–6 months following radiation of the bladder
[4] and is even more frequent in the interval of 3 months to
5 years. Cystitis is a common chemotherapy-associated
complication following intravesical adjuvant therapy for
urothelial malignancy. It occurs in up to 21 % of mito-
mycin C–treated patients and in up to 27 % of bacillus
Calmette–Gue´rin (BCG)–treated patients [5].
Nonbacterial cystitis following radiotherapy and topical
chemotherapy presents significant problems for those
affected and for health care professionals because of the
often unsuccessful long-term treatment [6]. Clinically, the
primary symptoms of cystitis are irritative urination and
pain, which can significantly reduce quality of life and can
possibly affect ongoing oncological therapy [7]. Recurrent
haematuria further complicates the situation.
To date, there are no consistent treatment recommen-
dations for the treatment of radiotherapy- and chemother-
apy-associated cystitis [8], and in everyday clinical and
outpatient practice in Germany, patients with radiotherapy-
or chemotherapy-associated cystitis represent an under-
served patient group [8]. Given the lack of a causal
approach to cystitis, treatment is limited to symptomatic
therapy with anticholinergics, analgesics and antibiotics
[8]. Furthermore, bladder instillations with chondroitin
sulphate have been shown to support the regeneration of
the damaged urothelium in patients with interstitial cystitis
[9].
While the clinical efficacy of chondroitin sulphate in
patients with interstitial cystitis has been investigated
thoroughly [9–11], few studies have investigated the effi-
cacy of this treatment in patients with radiotherapy- and
chemotherapy-associated cystitis [1, 13]. However, as the
pathophysiology of interstitial cystitis is similar to that of
radiotherapy- and chemotherapy-associated cystitis, it is
likely that instillation therapy with chondroitin sulphate
can also be effective in these patients [12, 13]. As such, the
objective of this study was to investigate the efficacy and
tolerability of short-term treatment with intravesical
chondroitin sulphate (Gepan instill; G. Pohl-Boskamp
GmbH & Co. KG, Hohenlockstedt, Germany) in patients




This observational, prospective study enrolled patients
aged C18 years with symptomatic radiogenic- or
chemotherapy-associated cystitis from July 2011 until June
2012. Patients were enrolled by the participating urologists
if they matched the inclusion and exclusion criteria and
were willing to take part in the study. Male and female
patients aged C18 years with a diagnosis of symptomatic
chronic radiogenic- or chemotherapy-associated cystitis
were eligible for the study. As this study was purely
observational, the diagnosis was mainly obtained from the
attending urologists’ patient records. No additional inva-
sive examinations were carried out. Patients were excluded
from the study if (1) they had a contraindication for
Gepan instill; (2) they were receiving concomitant ther-
apy with another glycosaminoglycan (GAG) replacement
treatment or another instillation therapy; (3) they were
participating in another clinical study; (4) they were
receiving antibiotics for an acute urinary tract infection; (5)
they were receiving other medications to treat their bladder
symptoms after study inclusion; or (vi) they were pregnant
(breastfeeding was not a specific exclusion criterion).
The study was conducted according to the ethical prin-
ciples of the Declaration of Helsinki, and the study pro-
tocol was reviewed and approved by the ethics committee
of the University of Leipzig (Ethik-Kommission an der
Medizinischen Fakulta¨t der Universita¨t Leipzig), Leipzig,
Germany. Written informed consent was obtained from all
patients prior to participation in the study.
2.2 Treatment
A total of six instillations of 0.2 % chondroitin sulphate
40 mL (Gepan instill) were administered weekly. The
first instillation was given after baseline characteristics and
demographics were collected at visit 1. The treatment was
applied (in accordance with the instructions for use) by a
trained nurse under the supervision of the attending urol-
ogist, or by the attending urologist. The bladder was
transurethrally catheterized with a single-use catheter.
After the bladder was completely emptied, the entire vol-
ume of the solution was instilled in the bladder. Patients
were advised to retain the instillation for at least 30 min.
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2.3 Outcomes
Patients were assessed at baseline before initiation of 0.2 %
chondroitin sulphate treatment and at each weekly study
visit until the end of treatment (visit 6). As the study design
was purely observational, the main objective was to
investigate the effectiveness and tolerability of the instil-
lation treatment. Data collected at baseline included the
patient characteristics and demographics, including age,
gender, type of cancer, duration of radiotherapy or
chemotherapy, cystoscopy findings (if available), previous
medications, concomitant medications, current symptoms
and duration of symptoms.
At each study visit, the following cystitis symptoms were
assessed in each patient, using a self-completed question-
naire: daytime and night-time urinary frequency (patients
reported their average number of micturitions during the
daytime and night-time, and the micturition count was
documented), urinary urgency, pollakisuria, urge frequency,
dysuria, lower abdominal pain and haematuria. With the
exception of urinary frequency, symptoms were assessed by
the patient, using a numerical rating scale (NRS). This
11-item NRS ranged from 0 (symptom free) to 10 (maximal
imaginable symptom intensity). Clinical improvement was
defined as a reduction in the NRS score of C1 point.
Patients were asked to provide their viewpoints on the
efficacy and tolerability of 0.2 % chondroitin sulphate
treatment at every study visit. Patients self-assessed the
severity of their symptoms as ‘symptom free’, ‘improved’,
‘unchanged’ or ‘worsened’. Moreover, at each study visit,
they were asked whether any abnormalities had occurred
during or after the instillation procedure (this was an open
question to encourage the patients to report anything out of
the normal). The patients’ urologists also provided their
viewpoints on the efficacy and tolerability of 0.2 %
chondroitin sulphate treatment. The urologists were asked
whether any adverse events had occurred and, if so, were
asked to document details of these events throughout the
study period.
2.4 Statistical Analyses
Because this was an observational study, no sample size
calculation was performed. Quantitative data are presented
as means, medians and ranges. Qualitative data are pre-
sented as absolute numbers and percentages.
Missing data were excluded from the statistical analysis.
All available patient data were consulted to assess tolera-
bility. Statistical calculations were generated using
Microsoft Excel (2003) and PRISM (version 4.0, Graph-
Pad). Calculation of significance levels was performed
using the Wilcoxon matched-pairs rank test. A p value of
\0.05 was defined as being significant.
3 Results
3.1 Patient Disposition and Baseline Characteristics
A total of 16 patients (mean age 68.5 years; 50 % male)
were included in the study. Baseline patient demographic
and clinical characteristics are listed in Table 1. The mean
time between the start of radiotherapy or chemotherapy and
the onset of instillation therapy was 2.8 years (minimum
0.4 years; maximum 21 years). For one patient, the period
between the start of chemotherapy and the start of instilla-
tion therapy was only 5 months. The time period for all
other patients between the start of radiotherapy or
chemotherapy and the start of instillation therapy was
C1 year. The majority of patients (n = 12; 75 %) had
received at least one treatment for cystitis before enrolment,
primarily antibiotics and/or anticholinergics. One patient
had received another instillation therapy, and three patients
had received analgesics (Table 1). The most common cys-
titis symptoms experienced by patients at baseline were
urinary urgency, pollakisuria and pain (Table 1).
3.2 Effectiveness
Overall, a rapid reduction of C1 point on the NRS in all
cystitis symptoms was observed after treatment with 0.2 %
chondroitin sulphate, independently of the underlying dis-
ease (Fig. 1). After one dose of 0.2 % chondroitin sulphate,
clinical improvement was observed in 6 of 16 patients
(38 %) (Fig. 2). In an additional 31 % of patients, there
was relief of symptoms after the second administration of
treatment. At the end of treatment, 80 % of patients either
had improved symptoms or were symptom free (Fig. 2). At
week 6, the cystitis symptoms of urinary urgency
(p = 0.0082), pollakisuria (p = 0.0022), urge frequency
(p = 0.0033) and lower abdominal pain (p = 0.0449) were
significantly improved from baseline. Furthermore,
haematuria, which was present in 9 of the 16 patients at
baseline, was completely resolved in all cases after
6 weeks. At week 6, the median micturition frequency was
decreased from nine to seven micturitions during the day,
and from four to two micturitions during the night.
3.3 Tolerability
Most patients who were included in this study (93 %)
evaluated the tolerability of intravesical chondroitin sul-
phate as ‘good’ or ‘very good’. This rating was congruent
with the evaluation by the attending urologists, who
assessed the tolerability as ‘good’ or ‘very good’ in 93 %
of the cases. There were no adverse events related to the
treatment with 0.2 % chondroitin sulphate during the study
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visits. One male patient terminated the instillation therapy
after the third instillation because of catheter intolerance
after the operation. This patient completed study visits 1–4
but was not available for visits 5 and 6.
4 Discussion
This investigator-initiated, observational, prospective study
investigated the influence of 0.2 % chondroitin sulphate
instillations on the symptoms of radiotherapy- or
chemotherapy-associated cystitis in 16 patients over a brief
observation period. The decisive rationale for this study
was to provide a therapeutic option, which, in contrast to
other symptom-oriented forms of cystitis treatment, influ-
ences the mechanism of development of chronic inflam-
mation and thus represents a causal-oriented therapeutic
approach. The results of this study showed that chondroitin
sulphate provides rapid improvements in the symptoms of
radiotherapy- or chemotherapy-associated cystitis.
Fig. 1 Changes from baseline in the degree of discomfort of cystitis
clinical symptoms (measured using a numerical rating scale [NRS],
ranging from 0 [symptom free] to 10 [maximum symptom intensity])
during intravesical treatment with 0.2 % chondroitin sulphate
(n = 15)
Table 1 Baseline patient characteristics (n = 16)
Baseline characteristic Value
















Atrophic mucosa 3 (27)
Hyperaemic mucosa 5 (45)
Destroyed mucosa 2 (18)





Physical measures 2 (17)
Instillation therapyb 1 (8)
Urinary frequency, median (range)
Number of urinations during the day 9 (5–15)
Number of urinations at night 4 (1–8)
NRS score, median (range)
Clinical symptoms
Pollakisuria 6 (3–9)
NRS[0, % patients 100
NRS[5, % patients 75
Urinary urgency 7 (3–10)
NRS[0, % patients 100
NRS[5, % patients 75
Urge frequency 7 (3–10)
NRS[0, % patients 100
NRS[5, % patients 75
Dysuria 4 (0–10)
NRS[0, % patients 81
NRS[5, % patients 31
Lower abdominal pain 3 (0–10)
NRS[0, % patients 69
NRS[5, % patients 25
Haematuria 2 (0–5)
NRS[0, % patients 56
Table 1 continued
Baseline characteristic Value
NRS[5, % patients 0
All values are expressed as n (%) unless stated otherwise
NRS numerical rating scale (ranging from 0 [symptom free] to 10
[maximum symptom intensity])
a Applicable to only 12 of the 16 patients
b Uropol (2 % chondroitin sulphate 20 mL)
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To explain why bladder instillations of chondroitin
sulphate are beneficial for the treatment of cystitis, it is
important to understand the pathophysiology of radio-
therapy- and chemotherapy-associated cystitis. Radio-
therapy and chemotherapy can damage the GAG layer of
the bladder, which leads to a loss of urothelial barrier
function [14, 15]. The GAG layer consists of negatively
charged sulphated polysaccharides, which are coupled to
a negatively charged anchor protein [16]. When the
integrity of the GAG layer and urothelial cells is dis-
rupted, the permeability for aggressive components in the
urine (potassium ions, proteases, calcium crystals, etc.) is
increased. This can increase the stimulation of sub-
urothelial pain fibres. In addition, these generated signals
are amplified within the suburothelial networks [17],
which explains the clinical symptoms of pain, pollak-
isuria and urinary urgency seen with cystitis. Finally,
damage to the GAG layer can lead to development of a
chronic transmural inflammatory process and promotion
of bacterial adhesion, causing patients to have recurrent
urinary tract infections [18]. The late stage of radio-
therapy-associated cystitis is characterized by an alter-
ation of the bladder wall, with angiopathy and interstitial
fibrosis (Fig. 3). The consecutive decrease in bladder
compliance and anatomical capacity can ultimately lead
to a complete loss of bladder function, and sometimes
the only possible therapeutic option remaining is a cys-
tectomy. Therefore, a crucial aspect for the success of
GAG replacement therapy is a urothelium that can still
be regenerated and is treated before ulceration and wall
fibrosis occur.
An available treatment that addresses the cause of
chronic cystitis is intravesical instillation of substances that
replace the GAG layer—a regimen that was successfully
introduced in the 1990s. While this treatment regimen can
now be regarded as established in the therapy of interstitial
cystitis, it is rarely used in radiotherapy- and chemother-
apy-associated cystitis. Of the different substances that are
used in GAG replacement therapy, chondroitin sulphate is
particularly suitable. Chondroitin sulphate is the GAG,
which is located mainly on the luminal side of the
urothelium and contributes to maintaining transepithelial
resistance [19]. Data from animal studies show that
instillation of chondroitin sulphate leads to restoration of
the permeability barrier [20]; thus, in the suburothelium,
the number of inflammatory cells decreases [12]. Further-
more, for intravesical chondroitin sulphate, it has been
proven that the GAG molecules selectively attach apically
to damaged areas of mucosa and do not penetrate into
deeper layers of the bladder wall [21]. As a result, reduc-
tions in clinical symptoms, particularly episodes of urinary
urgency, bladder pain and pollakisuria, have been observed
with chondroitin sulphate treatment in patients with inter-
stitial cystitis, overactive bladder, radiogenic cystitis and
recurrent urinary tract infections with corresponding GAG
layer defects [13], and in female patients with overactive
bladder [22].
To our knowledge, only one other study has specifically
investigated the use of 0.2 % chondroitin sulphate in
patients with radiotherapy- and chemotherapy-associated
cystitis [1]. In that pilot study, Hazewinkel and colleagues
showed that prophylactic intravesical administration of
Fig. 2 Proportions of patients
with cystitis who were symptom
free, had improved disease
symptoms, had unchanged
disease symptoms and had
worsened disease symptoms
after intravesical treatment with
0.2 % chondroitin sulphate at
each study visit (visits 2–4:
n = 16; visits 5 and 6: n = 15)
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0.2 % chondroitin sulphate reduced the symptoms of acute
radiotherapy- and chemotherapy-associated cystitis.
Patients treated with chondroitin sulphate experienced
significantly fewer urinary urgency symptoms than those in
the control group.
Although the current study and the pilot study reported
by Hazewinkel et al. [1] both showed the positive effect of
intravesical treatment with 0.2 % chondroitin sulphate, the
two studies cannot be compared, as they investigated dif-
ferent indications. While Hazewinkel et al. investigated the
potential effect of 0.2 % chondroitin sulphate in preventing
radiotherapy- and chemotherapy-associated cystitis, the
objective of the current study was investigation of the
treatment effect in patients with existing chronic radio-
therapy- and chemotherapy-associated cystitis.
As we were able to confirm in this study, an instillation
of 0.2 % chondroitin sulphate is an effective therapeutic
option for improving parameters that influence quality of
life in patients with radiotherapy- and chemotherapy-
associated cystitis. Considering the available data from the
current study, as well as that of Hazewinkel et al. [1],
treatment with 0.2 % chondroitin sulphate seems to be
useful in prevention and treatment of radiotherapy- and
chemotherapy-associated cystitis. In one recent study of
intensity-modulated radiation therapy (IMRT) in prostate
carcinoma, the 10-year risk of grade[2 toxicities of the
urinary tract was 17 % [23]. The extent to which patients
can benefit from GAG replacement therapy is not yet clear
and cannot be definitively assessed using the data available.
Experience from clinical practice indicates that GAG
replacement therapy is used relatively late. Considering the
mechanism of action of GAG replacement, the best pos-
sible benefit would involve promoting early use in order to
avoid urothelial destruction and fibrosis of the bladder wall.
This work was intended to investigate whether brief
treatment with intravesical therapies triggers a therapeutic
effect in these indications. Since a significant improvement
in symptoms was observed for most symptoms, even after
Fig. 3 Progressive forms of
radiogenic cystitis. Histological
image of the bladder wall,
trabeculae = 200 lm, Leipzig







(haematoxylin and eosin stain).
b Significantly flattened
urothelium, only a few cell
layers preserved (arrow) with
moderate lymphoplasmacellular
inflammation and proliferation
of capillaries in the lamina
propria (haematoxylin and eosin




collagen fibre proliferation and
capillary vascular proliferates in
the mucosal layer and
dissemination of the changes to
the superficial muscularis layer
(Elastica–van Gieson stain).
d Significantly flattened
mucosal layer with superficially
erosive chronic granulating
inflammation and reactive
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only five applications of chondroitin sulphate, brief
installations over short periods of time on a weekly basis
appear to be useful.
In the current study, there were two patients with
unaltered symptom intensity and one patient with even
worsened symptoms. It is not clear whether additional
instillations might have improved their symptoms. GAG
replacement therapy can be of limited effectiveness in
patients with very progressive disease. Additionally, high-
degree urge incontinence, highly limited bladder capacity
or advanced bladder wall alteration may limit the thera-
peutic benefit.
Cystoscopy was performed in 69 % of the patients prior
to the start of the study. We consider it mandatory to
collect cystoscopic baseline findings to record the extent of
the urothelial damage, even if the benefit cannot be proven
in this work. The cystoscopic findings, and particularly the
histopathological assessment, make it possible to optimize
the duration of treatment and the instillation intervals,
depending on the degree of urothelial damage. In addition,
in the event of a clinically unsatisfactory treatment, a
cystoscopic assessment of disease progression may be of
help. Since most patients have to undergo cystoscopy
anyway because of concurrent oncological issues, assess-
ing the composition of the mucosa via a resection biopsy
represents only a minimal additional burden for the patient.
The limitations of this study were its short duration and
the lack of a control group. The observation time period of
5 weeks in the current investigation represents only a short
period in the care of patients with chemotherapy-associated
and radiogenic cystitis. No follow-up was performed after
the final instillation, so the duration of effects could not be
evaluated. Although this observational study did not
include a control group, it still demonstrated measurable
improvements in a realistic therapeutic setting for the two
different chronic diseases studied. Moreover, this study
shows that chondroitin sulphate is a possible therapeutic
option for patients with multiple prior therapies, as it is
well tolerated and provides subjective improvements in
patient wellbeing, with the majority of patients reporting
symptomatic improvement.
We recommend that future studies of intravesical
chondroitin sulphate in radiotherapy- and chemotherapy-
induced cystitis should include long-term follow-up to
evaluate the duration of the therapeutic effect. Further-
more, the use of a standardized questionnaire would
facilitate comparison of the results from different studies.
5 Conclusion
If one summarizes the results of the study, the following
lessons can be learned:
• Brief application of chondroitin sulphate instillations
(six weekly instillations) leads to a significant improve-
ment in symptoms of chronic radiotherapy- or
chemotherapy-associated cystitis, which positively
influences the oncological therapeutic concept.
• Supportive instillation of chondroitin sulphate for
mucosal regeneration should be performed in the case
of persistent cystitis following radiation or topical
chemotherapy.
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